Robert A Figlin

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. doi request reprint Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma
    Robert A Figlin
    Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, USA
    Expert Opin Biol Ther 15:1241-8. 2015
  2. doi request reprint A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma
    Robert A Figlin
    Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Saperstein Critical Care Tower 1S28, Los Angeles, CA 90048, USA
    Immunotherapy 6:261-8. 2014
  3. doi request reprint Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors
    Robert A Figlin
    Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA 90048, USA
    Int J Cancer 133:788-96. 2013
  4. doi request reprint Novel agents and approaches for advanced renal cell carcinoma
    Robert Figlin
    Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Urol 188:707-15. 2012
  5. ncbi request reprint Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 103:2517-25. 2005
  6. ncbi request reprint Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    University of California Los Angeles Kidney Cancer Program, Department of Urology, University of California Los Angeles School of Medicine, Los Angeles, California 90095 1738, USA
    Cancer 98:2566-75. 2003
  7. ncbi request reprint Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection
    Allan J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    J Urol 169:2076-83. 2003
  8. ncbi request reprint Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy
    Allan J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles, California 90095 1738, USA
    Cancer 97:2995-3002. 2003
  9. ncbi request reprint Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy
    Amnon Zisman
    Kimmel Cancer Center, Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, USA
    J Urol 169:909-16. 2003
  10. ncbi request reprint Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy
    Karen L Reckamp
    Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA
    J Immunother 30:417-24. 2007

Detail Information

Publications70

  1. doi request reprint Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma
    Robert A Figlin
    Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, USA
    Expert Opin Biol Ther 15:1241-8. 2015
    ..AGS-003 is a novel autologous dendritic cell vaccine currently in Phase III clinical development in combination with sunitinib for patients with intermediate- and poor-risk clear cell metastatic renal cell carcinoma (ccmRCC)...
  2. doi request reprint A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma
    Robert A Figlin
    Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Saperstein Critical Care Tower 1S28, Los Angeles, CA 90048, USA
    Immunotherapy 6:261-8. 2014
    ..Some evidence suggests that certain targeted therapies, such as sunitinib, may reduce this immunosuppression and enhance the tumor microenvironment to promote synergy with autologous dendritic cell vaccines. ..
  3. doi request reprint Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors
    Robert A Figlin
    Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA 90048, USA
    Int J Cancer 133:788-96. 2013
    ..The future success of mRCC treatment will likely involve a combination of agents targeting the multiple pathways involved in angiogenesis, including VEGFR, PI3K and mTORC1/2...
  4. doi request reprint Novel agents and approaches for advanced renal cell carcinoma
    Robert Figlin
    Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Urol 188:707-15. 2012
    ..Many novel targeted agents, of which some have different mechanisms of action than approved agents, and immunomodulatory agents are currently in development for renal cell carcinoma...
  5. ncbi request reprint Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 103:2517-25. 2005
    ..The authors investigated the relation of tumor necrosis to other clinicopathologic factors known to be important prognostic indicators for patients with RCC...
  6. ncbi request reprint Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    University of California Los Angeles Kidney Cancer Program, Department of Urology, University of California Los Angeles School of Medicine, Los Angeles, California 90095 1738, USA
    Cancer 98:2566-75. 2003
    ..The objective of this study was to develop an algorithm capable of stratifying the survival of patients with metastatic renal cell carcinoma (RCC) after nephrectomy and immunotherapy...
  7. ncbi request reprint Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection
    Allan J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    J Urol 169:2076-83. 2003
    ..We better defined the benefits and morbidity of lymph node dissection in patients with localized renal cell carcinoma using the experience of patients treated at our institution...
  8. ncbi request reprint Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy
    Allan J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles, California 90095 1738, USA
    Cancer 97:2995-3002. 2003
    ..The current study was performed to determine the impact of the presence of retroperitoneal lymphadenopathy on the survival and response to immunotherapy of patients with metastatic renal cell carcinoma (RCC)...
  9. ncbi request reprint Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy
    Amnon Zisman
    Kimmel Cancer Center, Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, USA
    J Urol 169:909-16. 2003
    ..We outline the biology, prognosis and role of immunotherapy for renal cell carcinoma with gross venous tumor thrombus...
  10. ncbi request reprint Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy
    Karen L Reckamp
    Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA
    J Immunother 30:417-24. 2007
    ..The CXCR3/CXCR3 ligand biologic axis and angiogenic ratio may be important biomarkers in clear cell RCC patients who are undergoing high dose IL-2 therapy...
  11. ncbi request reprint Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma
    Ken ryu Han
    Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    Urology 61:314-9. 2003
    ..The most common sites of metastatic renal cell carcinoma (mRCC) are the lung and bone...
  12. ncbi request reprint Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    BJU Int 99:821-4. 2007
    ....
  13. ncbi request reprint Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Cancer 109:2257-67. 2007
    ..The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway in renal cell carcinoma (RCC)...
  14. ncbi request reprint Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma
    David B Seligson
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 10:2659-69. 2004
    ....
  15. ncbi request reprint Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
    J Urol 173:1853-62. 2005
    ..This review highlights such controversies and provides an update on current staging modalities, prognostic factors and targeted molecular therapy for RCC...
  16. ncbi request reprint Cystic renal cell carcinoma: biology and clinical behavior
    Ken ryu Han
    UCLA Department of Urology, Los Angeles, CA, USA
    Urol Oncol 22:410-4. 2004
    ..These findings suggest that cRCC patients may benefit from nephron sparing surgery...
  17. ncbi request reprint RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma
    Oleg Shvarts
    Department of Urology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1738, USA
    Urology 68:1132-8. 2006
    ..The specificity and the prognostic value of CA-IX provide impetus to create a mouse model of CA-IX-expressing RCC for testing CA-IX-targeted therapies against RCC...
  18. pmc Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
    Charles S Harmon
    Pfizer Oncology, 10646 Science Center Drive, La Jolla, San Diego, CA, 92121, USA
    Cancer Chemother Pharmacol 73:151-61. 2014
    ....
  19. ncbi request reprint Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different?
    Hyung L Kim
    Department of Urology, University of California School of Medicine, Los Angeles, 90095, USA
    J Urol 171:588-91. 2004
    ..The prognostic significance of the level of venous involvement in renal cell carcinoma (RCC) is controversial. It has been suggested that the 1997 TNM classification of venous involvement system should be revised...
  20. ncbi request reprint A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma
    Barbara J Gitlitz
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at University of California, Los Angeles, 10945 Le Conte Avenue, Suite 2333, Los Angeles, CA 90095, USA
    J Immunother 26:412-9. 2003
    ..Further clinical studies are needed to identify the most potent treatment regimen that can consistently mediate an antitumor immune response in vivo...
  21. ncbi request reprint Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis
    Hyung L Kim
    Department of Urology, School of Medicine, University of California Los Angeles, 10833 LeConte Avenue, Los Angeles, CA 90095, USA
    J Urol 170:1742-6. 2003
    ..To our knowledge we report the first study to describe the frequency of paraneoplastic findings in a modern RCC series and assess the prognostic significance of each finding...
  22. doi request reprint Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:1552-8. 2008
    ..On the basis of outcome data from that trial, the authors developed a nomogram for predicting the probability of 12-month progression-free survival for patients who received sunitinib therapy...
  23. ncbi request reprint Using protein expressions to predict survival in clear cell renal carcinoma
    Hyung L Kim
    Department of Urology, University of California School of Medicine, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 10:5464-71. 2004
    ....
  24. ncbi request reprint Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system
    John S Lam
    Division of Urologic Oncology, The Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, USA
    J Urol 174:466-72; discussion 472; quiz 801. 2005
    ..We created an evidence based postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma (RCC) based on a risk group stratification system...
  25. ncbi request reprint Surveillance following radical or partial nephrectomy for renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, 66 118 CHS, Box 951738, Los Angeles, CA 90095 1738, USA
    Curr Urol Rep 6:7-18. 2005
    ..Therefore, the timely identification of recurrences following surgical extirpation is imperative in the treatment of patients...
  26. ncbi request reprint Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9
    Hideki Mukouyama
    Departments of Urology and Medicine, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 10:1421-9. 2004
    ..The ability to consistently generate a T-cell response is an important step toward the development of a CA9-specific RCC vaccine...
  27. ncbi request reprint Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
    Allan J Pantuck
    Departments of Urology and Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
    Clin Cancer Res 13:693s-696s. 2007
    ..Although evidence-based medical practice suggests a role for nephrectomy before the use of targeted agents, the arguments for and against this practice will be weighed...
  28. ncbi request reprint Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma
    John T Leppert
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    BJU Int 96:281-5. 2005
    ....
  29. ncbi request reprint G250: a carbonic anhydrase IX monoclonal antibody
    John S Lam
    Department of Medicine, David Geffen School of Medicine at UCLA, 2333 Peter Ueberroth Building, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA
    Curr Oncol Rep 7:109-15. 2005
    ..These studies formed the basis of numerous clinical trials aimed at mAb-guided therapy in patients with metastatic RCC...
  30. ncbi request reprint Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience
    Tobias Klatte
    Department of Urology, University of California, Los Angeles, Los Angeles, California 90095 1738, USA, and Centre Hospitalier Universitaire Pontchaillou, Rennes, France
    J Urol 178:35-40; discussion 40. 2007
    ..We examined the current pT2 tumor classification of renal cell carcinoma and determined whether a tumor size cutoff exists that would improve prognostic accuracy...
  31. ncbi request reprint Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma
    Amnon Zisman
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA 90095 1738, USA
    J Clin Oncol 20:4559-66. 2002
    ..To create a comprehensive algorithm that can predict postoperative renal cell carcinoma (RCC) patient outcomes and response to therapy...
  32. pmc CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer
    Karen L Reckamp
    Department of Medical Oncology and Therapeutics Research, City of Hope and Beckman Research Institute, Duarte, CA, USA
    BMC Cancer 9:213. 2009
    ..This study was performed to evaluate the hypothesis that co-expression of pan-cytokeratin and CXCR4 may be a prognostic marker for patients with advanced NSCLC...
  33. ncbi request reprint Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience
    Jean Jacques Patard
    Department of Urology, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 171:2181-5, quiz 2435. 2004
    ..We compared cancer specific survival of patients undergoing partial and radical nephrectomies for T1N0M0 renal tumors according to tumor size in a large multicenter series...
  34. ncbi request reprint Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, USA
    BJU Int 96:483-8. 2005
  35. ncbi request reprint Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials
    John S Lam
    University of California Los Angeles Kidney Cancer Program, Division of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Le Conte Avenue, Los Angeles, CA, USA
    Clin Cancer Res 13:703s-708s. 2007
    ..This article reviews the protein expression profiles in RCC and their association with pathobiology, prognosis, and response to treatment as well as their role in serving as potential molecular targets for therapy of RCC...
  36. ncbi request reprint Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma
    Ken ryu Han
    Department of Urology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095, USA
    Urology 63:841-6; discussion 846-7. 2004
    ..Increasing numbers of patients requiring renal surgery are presenting with substantial comorbidities, such as diabetes mellitus, chronic obstructive pulmonary disease, and cardiovascular disease...
  37. ncbi request reprint Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype
    Amnon Zisman
    Department of Biostatistics, University of California Los Angeles School of Medicine, Los Angeles, CA, USA
    J Urol 168:950-5. 2002
    ..We characterized the histopathological features and clinical behavior of unclassified renal cell carcinoma and compared the prognostic outcome in patients with unclassified and conventional (clear cell) renal cell carcinoma...
  38. ncbi request reprint The role of molecular markers in the staging of renal cell carcinoma
    John T Leppert
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1738, USA
    BJU Int 99:1208-11. 2007
  39. ncbi request reprint A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer
    Karen L Reckamp
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at University of California at Los Angeles, 90095, USA
    Clin Cancer Res 12:3381-8. 2006
    ....
  40. ncbi request reprint Mathematical model to predict individual survival for patients with renal cell carcinoma
    Amnon Zisman
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA 90095 1738, USA
    J Clin Oncol 20:1368-74. 2002
    ..To develop a multivariate model and mathematical formula capable of calculating personalized survival for renal cell carcinoma (RCC) patients with clinically available variables...
  41. ncbi request reprint Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients
    Sylvia M Kiertscher
    Division of Pulmonary and Critical Care Medicine, UCLA School of Medicine, Los Angeles, CA 90095 1690, USA
    Int J Cancer 107:256-61. 2003
    ..These effects correlate with antigen-presenting activity, providing a mechanism by which systemic GM-CSF and IL-4 might stimulate anti-tumor immunity in vivo...
  42. ncbi request reprint Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 9:4641-52. 2003
    ....
  43. ncbi request reprint Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies
    Ganesh S Palapattu
    Department of Urology, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1738, USA
    J Urol 170:768-72; discussion 772. 2003
    ..To define further the prognostic impact of urothelial invasion in renal cell carcinoma (RCC) we examined the outcome in patients presenting to our institution with kidney cancer treated with nephrectomy...
  44. ncbi request reprint Advances in immune-based therapies of renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
    Expert Rev Anticancer Ther 4:1081-96. 2004
    ..Such strategies are currently being tested in clinical trials...
  45. doi request reprint Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha
    Robert A Figlin
    City of Hope Comprehensive Cancer Center, Duarte, CA, USA
    Cancer 115:3651-60. 2009
    ....
  46. doi request reprint Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 116:4256-65. 2010
    ..Final results and analysis of prognostic factors are reported...
  47. ncbi request reprint Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
    Nicolette K Janzen
    Department of Urology, University of California at Los Angeles School of Medicine, 10833 Le Conte Avenue, CHS 66 118, Los Angeles, CA 90095 1738, USA
    Urol Clin North Am 30:843-52. 2003
    ..Factors including patient comorbidities and patient willingness to pursue aggressive management in the event of recurrence may alter the follow-up for each individual...
  48. ncbi request reprint Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer
    Barbara J Gitlitz
    Division of Hematology Oncology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, USA
    J Immunother 26:171-8. 2003
    ..Systemic GM-CSF plus IL-4 provides a mechanism for increasing the number and function of APC in cancer patients. Future clinical applications of this strategy are numerous and include the potential as a strong vaccine adjuvant...
  49. ncbi request reprint Novel approaches in the therapy of metastatic renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, 66 118 CHS, Los Angeles, California 90095 1738, Box 951738, USA
    World J Urol 23:202-12. 2005
    ..The aim of this review is to provide an update on current therapeutic approaches and targeted molecular therapy for metastatic RCC...
  50. ncbi request reprint Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy
    John S Lam
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 44195, USA
    Clin Cancer Res 10:6304S-9S. 2004
    ..This article reviews the tissue array-based predictors of pathobiology, prognosis, response to treatment, and potential molecular targets for therapy of renal cell carcinoma...
  51. ncbi request reprint Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma
    John S Lam
    Department of Urology, University of California Los Angeles Kidney Cancer Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
    J Clin Oncol 24:5565-75. 2006
    ..This review will examine the evolving principles in the surgical management of RCC as well as provide an update on current staging modalities and prognostic factors...
  52. ncbi request reprint Cell, gene and vaccine based strategies in kidney cancer
    Barbara J Gitlitz
    University of California Los Angeles, 10945 Le Conte Avenue, Suite 2333, Los Angeles, CA 90095, USA
    Cancer Treat Res 116:183-98. 2003
  53. ncbi request reprint Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment
    Robert D Suh
    Department of Radiological Sciences, UCLA Medical Center, 10833 Le Conte Ave, B2 168 CHS, Los Angeles, CA 90095 1721, USA
    Radiology 231:359-64. 2004
    ..To assess the technical feasibility and safety of weekly outpatient percutaneous computed tomographic (CT)-guided intratumoral injections of interleukin-2 (IL-2) plasmid DNA in a wide variety of superficial and deep tumor sites...
  54. ncbi request reprint Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy
    Matthew H T Bui
    Department of Urology, University of California, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 9:802-11. 2003
    ..To date, there are no molecular markers which can reliably predict RCC outcome. We investigated whether a novel kidney cancer marker, carbonic anhydrase IX (CAIX), is associated with progression and survival...
  55. pmc Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Chemother Pharmacol 74:739-50. 2014
    ....
  56. ncbi request reprint Cytokine-based therapy for metastatic renal cell cancer
    Barbara J Gitlitz
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at University of California, Los Angeles, 2333 PVUB, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA
    Urol Clin North Am 30:589-600. 2003
    ..In the meantime, the knowledge gained clinically and in the laboratory should lead to continued improvements and outcomes in immunotherapy for RCC...
  57. ncbi request reprint The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma
    Javier Mestas
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 1786, USA
    J Immunol 175:5351-7. 2005
    ..These data support the notion that CXCR2/CXCR2 ligand biology is an important component of RCC tumor-associated angiogenesis and tumorigenesis...
  58. ncbi request reprint Adjuvant treatment for renal cell carcinoma
    John S Lam
    David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Expert Opin Pharmacother 7:705-20. 2006
    ..This review will discuss the role and current status of adjuvant therapies for renal cell carcinoma...
  59. ncbi request reprint Prognostic factors in renal cell carcinoma
    Brian M Shuch
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
    Semin Oncol 33:563-75. 2006
    ..The aim of the current review is to highlight such controversies and provide an update on current staging modalities and prognostic factors for RCC...
  60. ncbi request reprint Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
    Kenneth A Foon
    Abgenix, Inc, Fremont, CA, USA
    Int J Radiat Oncol Biol Phys 58:984-90. 2004
    ..Therapy was generally well tolerated without statistically significant adverse events. Monoclonal antibody blockade of EGFR represents a new and exciting direction in cancer therapy...
  61. ncbi request reprint Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1738, USA
    Semin Oncol 33:607-13. 2006
    ....
  62. ncbi request reprint Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:16-24. 2006
    ..SU11248 (sunitinib malate), a small molecule inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clinical activity in patients with metastatic RCC...
  63. ncbi request reprint Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma
    Wei Cao
    Department of Epidemiology, UCLA School of Public Health, and Jonsson Comprehensive Cancer Center, Los Angeles, California 90095 1772, USA
    Cancer 104:2400-8. 2005
    ..GSTP1 may play a role in detoxification of tobacco-related carcinogens...
  64. pmc A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models
    Hao Zhang
    Department of Surgery Division of Urology, Cedars Sinai Medical Center, Los Angeles, California, USA
    PLoS ONE 8:e54918. 2013
    ..Furthermore, expression levels of VEGF and PDGF were lower in Caki-1 and 786-O cells treated with temsirolimus than cells treated with Ku0063794...
  65. ncbi request reprint Immune gene therapy for kidney cancer: the search for a magic trigger
    Hyung L Kim
    Department of Urology, University of California at Los Angeles, 10833 Le Conte Avenue, CHS 66 118, Los Angeles, CA 90095 1738, USA
    Mol Ther 7:153-4. 2003
  66. doi request reprint Targeting angiogenesis in renal cell carcinoma
    Edwin M Posadas
    Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Urologic Oncology Program, 8700 Beverly Blvd, Los Angeles, CA 90048, USA 1 310 423 7600 1 310 659 3928
    Expert Opin Pharmacother 14:2221-36. 2013
    ....
  67. pmc Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma
    Sumanta Kumar Pal
    Division of Genitourinary Malignancies, Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, CA, USA
    Target Oncol 6:5-16. 2011
    ..The application of mTOR inhibitors in unique populations is also described...
  68. ncbi request reprint Systemic therapy in renal cell carcinoma: advancing paradigms
    Edwin M Posadas
    Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Oncology (Williston Park) 26:290-301. 2012
    ....
  69. ncbi request reprint A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma
    Barbara J Gitlitz
    Division of Hematology Oncology, University of California Los Angeles School of Medicine, Los Angeles, California 90033, USA
    Cancer 98:1863-9. 2003
    ....
  70. ncbi request reprint Collecting duct renal cell carcinoma: clinical study of a rare tumor
    Debby Chao
    Department of Urology, Division of Urologic Oncology, University of California School of Medicine Los Angeles, Los Angeles, CA, USA
    J Urol 167:71-4. 2002
    ..The clinical and pathological features of 6 patients with collecting duct carcinoma treated at a single institution are described...